Dermaheal consent form and treatment record template

Dermaheal is a Korean mesotherapy range, but many practitioners still document it on paper consent forms or generic templates. These generic forms rarely capture the screening detail and protocol structure this treatment requires. Without structured records of patient screening, batch numbers, and session-by-session protocols, practices lose the treatment traceability regulators expect.

This guide covers what Dermaheal is, the six product lines and their indications, and how to administer the treatment safely. You’ll also find contraindications to screen for and storage requirements. Plus, there’s a downloadable consent and treatment record template you can customize for your practice. Whether you’re introducing Dermaheal to your offerings or refining your existing protocols, this resource provides the clinical and governance framework modern practices need.

Key takeaways

Dermaheal is a Korean mesotherapy range by Caregen containing biomimetic peptides and growth factors for professional clinical use.

Six core product lines (HSR, SR, SB, HL, LL, Eye Bag) target distinct skin concerns via needle mesotherapy, microneedling, or electroporation.

Practitioners must screen for contraindications and obtain documented informed consent before each treatment session.

Practice management software like Pabau streamlines compliance documentation and treatment traceability with digital consent forms and per-session records.

What is Dermaheal? A professional mesotherapy overview

Dermaheal is a range of professional-grade mesotherapy cocktails manufactured by Caregen Co., Ltd., a South Korean biotechnology company specializing in biomimetic peptide research. Each Dermaheal product is supplied as a sterile vial containing a proprietary blend of growth factors, biomimetic peptides, amino acids, vitamins, and minerals. The formulation supports subcutaneous injection, topical delivery via microneedling, or transdermal electroporation.

Unlike generic mesotherapy cocktails, Dermaheal formulations are indication-specific. Each product targets a distinct skin concern – anti-aging, rejuvenation, brightening, hair loss, eye bags, or body contouring – with a matched peptide complex. Practitioners administer Dermaheal within a digital consent framework that documents patient suitability, treatment expectations, and post-care instructions. This ensures clinical governance and informed consent standards are met before needle-to-skin contact.

Caregen’s research into biomimetic peptides and skin regeneration has been documented in the Journal of Cosmetic Dermatology, a peer-reviewed publication covering aesthetic treatment outcomes. The signature component of Dermaheal is its biomimetic peptides: synthetic peptides that mimic natural growth factors. They signal skin cells to stimulate collagen production, improve hydration, and reduce visible signs of aging and other skin concerns.

Product lines at a glance

Dermaheal offers six core formulations, each with distinct indications and peptide profiles. Below is a quick reference comparing the product variants, their target concerns, and typical treatment frequency.

Each product is supplied in sterile glass vials and must be stored under cold-chain conditions. Treatment frequency and session count vary by product line and patient response; always consult the manufacturer’s Instructions for Use (IFU) for definitive protocol guidance.

Key ingredients and what they do

Dermaheal formulations share a core set of ingredient classes, each serving a specific role in stimulating skin regeneration.

• Biomimetic Peptides: The signature component. These synthetic peptides mimic natural growth factors, signaling fibroblasts to produce collagen and elastin. Different peptide sequences target different concerns (anti-aging, brightening, hair growth).
• Growth Factors (EGF, FGF): Epidermal Growth Factor and Fibroblast Growth Factor drive cellular proliferation and tissue repair. Each Dermaheal line includes growth factors matched to its clinical indication.
• Amino Acids: Essential and non-essential amino acids provide the building blocks for new collagen and skin matrix proteins.
• Vitamins and Minerals: Antioxidants (vitamins C, E) and trace minerals (zinc, selenium) protect against oxidative stress and support cell metabolism during the healing phase.
• Hyaluronic Acid (select products): A hydrating polysaccharide that binds water and maintains skin plumpness, used in rejuvenation and brightening formulations.

The exact peptide blend differs by product line. Consult the product datasheet or IFU for the complete ingredient list and concentration data relevant to your clinical protocols.

Delivery methods: How treatments are administered

Dermaheal can be delivered via three distinct professional methods, each suited to different clinical scenarios and anatomical zones.

1. Needle Mesotherapy (Traditional Injection): A fine-gauge needle injects Dermaheal into the dermal or subdermal layer. This method allows precise product placement and is ideal for localized areas (face, scalp, eye zone). Practitioners typically use a 4mm or 6mm needle at 45-degree angles, injecting 0.1-0.2 mL per site. Post-injection, slight swelling and erythema are normal and typically resolve within 24-48 hours.
2. Microneedling (Dermaroller or Dermapen): A dermaroller (0.5-1.5 mm) or motorized dermapen creates microchannels in the epidermis, allowing topical Dermaheal serums to penetrate. This method is gentler than injection, reduces discomfort, and is suited to larger body areas or sensitive skin. Practitioners apply Dermaheal as a topical serum during or immediately after microneedling, allowing the product 15-20 minutes to absorb.
3. Transdermal Electroporation (No-Needle Option): Low-frequency electrical pulses create temporary pores in the stratum corneum, allowing peptides to penetrate without needle insertion. This option appeals to needle-phobic patients and can be combined with other modalities. Electroporation devices come with pre-set parameters; follow manufacturer guidelines for voltage, duration, and frequency.

The choice of delivery method depends on patient preference, treatment area, skin sensitivity, and your practice’s equipment. Many practitioners combine methods within a single treatment course (e.g., injection for the face, microneedling for body areas).

Indications and contraindications

Before administering any Dermaheal product, conduct a thorough pre-treatment consultation and document patient suitability in your digital consent form. The screening process protects both patient safety and your practice’s clinical governance.

Common indications (suitable candidates for Dermaheal):

• Fine lines, wrinkles, and loss of skin elasticity (HSR)
• Dull or dehydrated skin lacking radiance (SR)
• Hyperpigmentation, melasma, or uneven skin tone (SB)
• Hair thinning or early-stage androgenetic alopecia (HL)
• Periorbital puffiness, dark circles, or under-eye laxity (Eye Bag Solution)
• Localized fat deposits or body sagging (LL)

Absolute contraindications (do not treat):

• Pregnancy or active breastfeeding
• Active skin infection, herpes simplex, or chickenpox in the treatment area
• Severe immunosuppression (HIV/AIDS, autoimmune diseases, recent transplant)
• Uncontrolled diabetes
• Bleeding disorders or anticoagulant therapy (relative; assess case-by-case)
• Known hypersensitivity to any product ingredient
• Severe active acne with pustules (defer until cleared)

Relative contraindications (assess and document carefully):

• Recent cosmetic procedures (Botox, fillers) in adjacent areas – allow 2 weeks clearance
• Active rosacea or sensitive skin – may require patch testing or lower frequency
• Perioral dermatitis – avoid injection in affected zones
• Tattoos in the treatment area – risk of ink dispersion with injection
• Nickel sensitivity – some needle materials may trigger reactions

For UK practitioners, the Save Face register offers evidence-based guidance on practitioner registration, accreditation, and safe aesthetic treatment protocols. This guidance aligns with informed consent best practices. Always consult the manufacturer’s IFU and your practice’s medical director before treating any patient with relative contraindications. Document your clinical reasoning in the patient record.

Storage, handling, and shelf life

Dermaheal products are supplied as sterile vials and require strict cold-chain management to preserve peptide integrity and efficacy.

• Storage Temperature: 2-8°C (refrigerator). Do NOT freeze.
• Shelf Life: Typically 24-36 months from manufacture date when stored correctly. Check the vial label for the specific expiry date.
• Light Protection: Store in original packaging away from direct sunlight.
• Handling: Before use, allow vials to reach room temperature (5-10 minutes). Do not use vials that show signs of discoloration, cloudiness, or crystallization.
• Opened Vials: Single-use vials are recommended. If a multi-dose vial is opened, use within 24 hours and maintain sterile technique.
• Post-Opening Stability: Once reconstituted or opened, Dermaheal serums should be used within the session; do not store partially used vials.

Implement a stock rotation system (FIFO – First In, First Out) and maintain temperature logs for your practice refrigerator to ensure compliance with cold-chain requirements. Poor storage compromises product efficacy and may invalidate your informed consent – document your storage procedures in your practice’s standard operating procedures.

Treatment protocol guide and session planning

Effective Dermaheal outcomes depend on consistent protocol adherence. The downloadable treatment record template (link in the card at the top) lets you document each session’s product, batch number, and vial volume. It also captures delivery method, anatomical site, post-treatment observations, and patient feedback, creating an auditable per-session record for clinical governance and safety traceability.

General protocol principles across all Dermaheal lines include an initial course of 4-6 weekly sessions. Maintenance sessions follow every 4-8 weeks, depending on patient response and product line. The exact frequency should be customized based on individual skin condition, patient tolerance, and clinical results. Always frame treatment timelines with patients during the consent conversation and adjust protocols based on observed outcomes.

Within your practice’s client record system, link each treatment to the session record template, embedding the protocol, vial details, and aftercare instructions. This digital linkage ensures continuity and makes it easy to review historical treatments when assessing cumulative results or troubleshooting any adverse responses.

Post-treatment care and patient instructions

Post-treatment instructions are critical for patient satisfaction and safety. Provide written aftercare guidance within your digital consent framework so patients have a record they can reference at home.

• First 24 hours: Avoid vigorous exercise, hot showers, or extreme temperature exposure. Mild erythema and swelling are normal and typically resolve within 24-48 hours.
• Skincare: Use gentle, fragrance-free cleansers and moisturizers. Avoid active ingredients (vitamin A, acids) for 48 hours post-treatment.
• Sun Protection: Strict SPF 30+ sunscreen daily for at least one week post-treatment, especially for brightening (SB) treatments.
• Avoiding Products: No alcohol, retinoids, or exfoliants for 3-5 days.
• Needle Site Care (if using mesotherapy injection): Avoid touching or scratching injection sites. If minor scabbing occurs, do not pick – allow natural healing.
• Hydration: Encourage patients to drink water and maintain skin moisture with a hydrating serum.
• Follow-Up Sessions: Confirm next appointment before the patient leaves. Use automated workflows to send reminders 24 hours before scheduled treatments.

Your practice’s aftercare instructions should align with NHS best practices for wound care and infection prevention to ensure patient safety standards are met. Any unusual reactions (prolonged erythema, infection signs, allergic response) should prompt immediate contact with the practice. Document all patient feedback and adverse events in the treatment record for continuous quality improvement.

When to refer or escalate

Despite thorough screening, some patients will be unsuitable or develop complications requiring escalation. Know when to refer out.

• Pregnancy or suspected pregnancy: Defer treatment and advise patient to consult their GP.
• Uncontrolled medical conditions (diabetes, hypertension): Request medical clearance from the patient’s GP before proceeding.
• Severe allergic reaction during patch testing: Stop, document, and refer to allergy services if indicated.
• Signs of infection post-treatment (purulent drainage, fever, spreading erythema): Advise immediate GP consultation; consider antibiotics.
• Excessive bruising, hematoma, or prolonged edema: Assess for coagulopathy; refer to hematology if recurrent.
• Neurological symptoms (numbness, weakness near injection site): Possible nerve involvement; refer to neurology.

Document all referrals and clinical decisions in the patient record. This creates a safety trail and supports your practice’s governance framework when audited by regulators (CQC, HIS, MHRA).

How Pabau streamlines Dermaheal consent and treatment records

Most practices running Dermaheal protocols track consent on paper, then log batch numbers, vial volumes, and session notes in a separate spreadsheet. Those records rarely connect back to the specific product used, the practitioner who administered it, or the aftercare instructions the patient received.

Pabau’s digital consent forms capture the same screening and contraindication questions this template covers, then attach directly to the patient’s record. Each treatment note logs the product line, batch number, vial volume, delivery method, and practitioner, so every Dermaheal session has a documented, auditable trail.

Automated appointment reminders and aftercare messages go out without front-desk staff typing them by hand. Before-and-after photos attach to the same record as the consent form and treatment note. When a regulator asks for the full history behind one session, the practice pulls it from a single screen instead of three separate systems.

Streamline your Dermaheal protocols with Pabau

Manage patient consent, document treatment records, track batch numbers, schedule follow-ups, and store before-and-after photos in one integrated practice management platform.

Book a demo

Conclusion

Dermaheal mesotherapy is a sophisticated, indication-specific treatment that demands careful patient selection, precise documentation, and meticulous follow-up. The clinical and governance framework – screening, consent, per-session records, and post-care instructions – is as important as the product itself.

Using a structured digital consent form and treatment record template (like the downloadable templates linked above) keeps your practice compliant and ensures continuity of care. It also gives your team a single source of truth for each patient’s treatment history. Book a demo to see how practice management software can embed Dermaheal protocols, consent workflows, and treatment records into one system.

Continue your research

Need to document treatment outcomes? Before-and-after photo capture helps you and your patients track Dermaheal results over time.

Want to automate patient reminders? Email and SMS campaigns can send pre-treatment prep instructions and post-care reminders to your entire patient list.

Looking for a medical director or compliance partner? How to hire a medical director for your med spa covers governance best practices and staffing models.

Frequently asked questions